Tuesday, October 26, 2004

Business World: Vasogen and Parkinson's Disease

A company press release concerning a presentation at Neuroscience 2004:
Vasogen's VP025 Provides a Neuroprotective Effect in Preclinical Model of Parkinson's Disease

TORONTO, Oct. 26 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a researcher and developer of immune modulation therapies targeting chronic inflammation, today announced the presentation of preclinical research demonstrating the ability of VP025 to provide a significant neuroprotective effect in a model of Parkinson's disease. The research, carried out by the Department of Anatomy/Neuroscience, Biosciences Institute, University College Cork, Ireland, was presented at Neuroscience 2004, the Society for Neuroscience's 34th Annual Meeting in San Diego.

"The ability of VP025 to offer a protective effect in the brain and reduce neuron death in this preclinical model suggests that this drug may have potential in the treatment of Parkinson's disease," said Dr. Aideen Sullivan, principal investigator for this study at University College Cork. "It is also encouraging to note that these data are consistent with other research being presented at this conference this week, which highlight the positive anti-inflammatory effects of VP025 in other preclinical models."

[ ... Read the full press release ... ]

No comments: